Lastly, Altiratinib, a balanced MET/Tie2/VEGFR2 inhibitor, has been shown to substantially reduce tumor size, microvessel density, TEM infiltration, and the invasion potential of GBM cells in combination with Bevacizumab [306]. Here, TEK is linked to glioblastoma.